Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 11/20 | 0.34 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.33 |
| ▸ | UBE2N | P61088 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5365940 | 0.70 | LMNA (0.40) | LMNATP53MAPTRAB9AKMT2A | |
| SCHEMBL6108108 | 0.67 | LMNA (0.47) | LMNATP53MAPTMEN1RAB9A | |
| SCHEMBL5368045 | 0.66 | LMNA (0.44) | LMNATP53MEN1RAB9AKMT2A | |
| SCHEMBL4980062 | 0.64 | KMT2A (0.44) | LMNATP53MAPTRAB9AKMT2A | |
| SCHEMBL11375532 | 0.62 | LOXL2 (0.37) | LMNATP53RAB9AKMT2ALOXL2 | |
| SCHEMBL6042880 | 0.61 | KMT2A (0.45) | LMNATP53MAPTMEN1NPC1 | |
| SCHEMBL1442168 | 0.60 | MAPT (0.43) | LMNATP53MAPTMEN1NPC1 | |
| SCHEMBL5365540 | 0.60 | LMNA (0.47) | LMNATP53MAPTMEN1RAB9A | |
| SCHEMBL9360855 | 0.60 | SMN1; SMN2 (0.43) | LMNATP53MAPTMEN1NPC1 | |
| SCHEMBL5367572 | 0.60 | KDM4E (0.40) | LMNATP53MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677339-B2 | S-3-(4-(3,5-DICHLOROPYRID-4-YLCARBOXAMIDO)PHENYL)-2-(4,6-DIMET HOXY-1,3,5-TRIAZIN-2-YLAMINO)PROPANOIC ACID FOR EXAMPLE; INHIBIT BINDING OF ALPHA 4 INTEGRINS TO THEIR LIGANDS, FOR TREATING IMMUNE OR INFLAMMATORY DISORDERS | CELLTECH R & D LIMITED (GB) | 2004-01-13 | — | — | US | disclosed |
| US-20020028812-A1 | Phenylalanine derivatives | CELLTECH CHIROSCIENCE LIMITED (GB) | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028812-A1 | Phenylalanine derivatives | PAH, FPR1, VCAM1 | LMNA 2207/4885TP53 1412/4885MAPT 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.